| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Manuel Rodríguez, Juan Manuel Pascasio, Enrique Fraga, Javier Fuentes, Martín Prieto, Gloria Sánchez, José Luis Calleja, Esther Molina, María Luisa García-Buey, Maria Ángeles Blanco, Javier Salmerón, María Lucia Bonet, José Antonio Pons, José Manuel González, Miguel Ángel Casado, Francisco Jorquera and the TENOSIMP-B Research Group |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Gilead Sciences SL collaborated in the unconditional funding of the TENOSIMP-B study |
|
|
| Corresponding Author |
Manuel Rodríguez, MD, Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain. amunoz@porib.com |
| Key Words |
Hepatitis B; Tenofovir; Lamivudine+Adefovir; Efficacy; Safety; Adherence; Costs |
| Core Tip |
The Tenosimp-B study was performed to demonstrate the non-inferiority (15% non-inferiority limit) of tenofovir disoproxil fumarate (TDF) monotherapy versus the combination of lamivudine+adefovir (LAM+ADF) in 46 patients with chronic hepatitis B (CHB) and resistance to LAM (22 with TDF and 24 with LAM+ADV). TDF demonstrated its safety (no significant differences in adverse events (AEs), kidney function or liver function) and non-inferiority in maintaining virologic response (undetectable hepatitis B virus DNA [HBV-DNA] and negative for hepatitis B e antigen [HBeAg]) during the study, without differences in adherence to treatment. Additionally, the use of TDF resulted in significant savings in hospital costs. |
| Publish Date |
2017-11-05 00:48 |
| Citation |
Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F, Group TTBR. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World J Gastroenterol 2017; 23(41): 7459-7469 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i41/7459.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i41.7459 |
